# Personalized Therapy for Esophagogastric Cancer Using Thymidylate Synthase Genetic Markers

> **NCT02296671** · PHASE2 · WITHDRAWN · sponsor: **Washington University School of Medicine**

## Conditions studied

- Esophagogastric Cancer

## Interventions

- **DRUG:** Pemetrexed
- **DRUG:** Oxaliplatin
- **DRUG:** Leucovorin
- **DRUG:** Fluorouracil
- **GENETIC:** Germline genotyping analyses for TSER

## Key facts

- **NCT ID:** NCT02296671
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2015-02
- **Primary completion:** 2018-09
- **Final completion:** 2022-02
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Was unable to accrue any patients
- **Last updated:** 2016-03-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02296671

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02296671, "Personalized Therapy for Esophagogastric Cancer Using Thymidylate Synthase Genetic Markers". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02296671. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*